Anesthesia is vital when treating patients with significant dental anxiety. The challenge often lies in deciding which anesthesia to use. Researchers at the Tokyo Dental College compared the use of propofol and sevoflurane in 20 patients who had severe anxiety about their dental surgery, as well as their recovery and satisfaction, to find which is better. All of the patients were healthy, and none had been given general anesthesia for prior dental treatment.
At 2 different appointments, each patient was anesthetized with either propofol or sevoflurane alone. Patients were given the same drug to eliminate any movement, and a breathing tube was used. The single-drug anesthetic had never been studied. Patients were always given opioids or nitrous oxide to keep them anesthetized throughout the procedure, making it difficult to pinpoint the effects of the primary painkilling drugs themselves.
The researchers found no differences between the drugs in terms of recovery. Although patients came out of anesthesia more quickly with sevoflurane than with propofol, all patients were discharged at a similar time. A few had nausea while recovering from sevoflurane, but none reported complications 24 hours later. All patients were able to eat their first meal and drink fluids at a similar time, and none experienced nausea or vomiting once leaving the dentist’s office.
However, patients revealed a clear preference for propofol after being anesthetized with each drug. They said they had more discomfort and fatigue after taking sevoflurane. Some also said they disliked the smell of sevoflurane. Even though some patients reported more pain during the injection of the propofol, 80% of the patients in the study said they would choose propofol for future surgeries.
The researchers concluded that propofol is the anesthetic of choice for dental patients with severe anxiety about surgery, but these patients may continue to need general anesthesia in future surgeries. When patient satisfaction is the highest priority, the researchers suggest that dentists may want to give propofol during in-office surgery.
DentLight’s Nano Freedom LED Light is engineered to be super-lightweight, with only 3 g of weight on the nose bridge. Also, its unique, touch-free battery design disperses weight evenly across the head, with little extra weight on the nose or ear. It fits with all major loupes and eyewear frames as well.
Packed with innovative technologies, the Nano Freedom offers uniform color temperature light using exceptional optics; a focused, shadow-free beam of 20,000-lux intensity; freedom from the hassle of managing the cords and battery packs of traditional LED lights; noncontact, hands-free activation; and an economical, rechargeable lithium-ion battery that runs for longer than 3 hours with a one-hour recharging time.
For more information, call DentLight at (800) 763-6901 or visit dentlight.com/product/nanofreedom.
Numerous studies have shown that problems with oral health are strong co-indicators of other serious diseases such as diabetes, cancer, and cardiovascular disease. Now, a research team will explore innovative treatment options for periodontal diseases, specifically exploring ways to use combinatory antimicrobial approaches to disrupt biofilm such as plaque to increase the effectiveness of treating harmful oral bacteria.
Titled “Novel Strategies for Treatment of Periodontal Disease and Remediation of Oral Dysbosis,” the project comprises researchers from Wilfrid Laurier University, McMaster University, and the University of Toronto, as well as Mirexus Biotechnologies, funded by a GlycoNet Collaborative Team Grant. Also known as the Canadian Glycomics Network, GlycoNet is a pan-Canadian, multidisciplinary research network funded by the Canadian government aimed at delivering solutions to important health issues via the study of glycomes.
Mirexus Biotechnologies produces PhytoSpherix, an edible, water soluble, and biodegradable nanomaterial that’s chemically identical to glycogen and extracted from non-genetically modified corn. The human body stores glycogen, which is a natural polysaccharide, as a source of energy. Mirexus is currently investigating how PhytoSpherix can be leveraged across a variety of personal care applications.
The researchers aim to characterize biofilms formed during the establishment of a normal microflora compared to co-cultures of periodontal pathogenic organisms. Also, they will evaluate the changes to perio-pathogenic biofilms versus normal oral biofilms when challenged with combinations of various therapeutic and biofilm-disruptive additives to suggest novel treatment options that can be evaluated.
According to GlycoNet, Canadians spent approximately $12.8 billion on dental care and treatment costs in 2009, which was second in the nation only to cardiovascular disorders. Considering this financial burden as well as the increased risk of mortality associated with periodontal diseases and their connection with other systemic illnesses, the researchers believe that identifying innovative periodontal treatment options is a major health priority.
“GlycoNet’s support has brought together a unique team to tackle an important problem, and we will be excited to focus on this new opportunity in the commercialization of our unique, natural nanomaterial,” said Phil Whiting, president and CEO of Mirexus.
The 2017 KOL Access Webinar Series from OraVital Inc. will kick off with a pair of free sessions from pioneers in the oral-systemic health movement, Bradley Bale, MD, and Amy Doneen, DNP, ARNP, who are the authors of the bestselling book Beat the Heart Attack Gene. They also are coauthors of “High-Risk Periodontal Pathogens Contribute to the Pathogenesis of Atherosclerosis,” published by the British Medical Journal (BMJ) and the Postgraduate Medical Journal (PGMJ).
“This is a groundbreaking report that further validates the oral-systemic health link in general and, more specifically, the perio-cardio link,” said Dr. Jim Hyland, CEO of OraVital. “The PGMJ/BMJ manuscript clearly states, ‘periodontal disease due to high-risk pathogens is a cause of arterial disease.’ Now more than ever, dental clinicians can and should strengthen their commitment identifying and managing this form of periodontal disease.”
Bale will present the first webinar, “High-Risk Periodontal Pathogens Contribute to the Pathogenesis of Atherosclerosis,” on Thursday, February 9, at 8:30 pm est. He will discuss why periodontal disease due to high-risk pathogens must be considered a contributory cause of arterial disease and how the dental community has a significant opportunity to favorably impact the nation’s number one cause of death and disability—heart disease—by managing this type of periodontal disease.
Doneen then will present “Integrating the Science of Oral/Systemic Health into Clinical Practice” on Thursday, March 9 at 8:30 pm est. She will describe why it is necessary to respect the clinical context for which the information in the BMJ/PGMJ study can be applied to the clinical dental arena as well as why lines of communication must be created between medicine and dentistry that can clearly articulate the importance of understanding the oral pathogen burden as it relates to the vascular health of the individual patient.
Bale is an adjunct professor at the Texas Tech University Health Science Center, medical director of the Heart Health Program at Grace Clinic in Lubbock, Tex, and co-founder of the Bale/Doneen Method, which has been shown to halt, stabilize, and regress arterial disease. Doneen, also a co-founder of the Bale/Doneen Method, is medical director of the Heart Attack & Stroke Prevention Center and an adjunct professor at Texas Tech University Health Sciences.
Vista Dental Products’ Dripless Syringe—the world’s only dripless syringe, according to the company—features antidrip technology that greatly reduces the risk of bleach stains and damage to skin, eyes, and oral mucosa. Also, it costs no more than a standard irrigating syringe. It features a unique, color-coded plunger to quickly identify sodium hypochlorite (NaOCl) and a color-coded ring for improved visibility in magnified fields. It is available in untipped and pretipped 6-cc and 12-cc syringes.
For more information, call Vista Dental Products at (877) 418-4782 or visit vista-dental.com.
The global dental consumables market will grow from its 2016 total of $25.45 billion at a compound annual growth rate of 6.8% to reach $35.35 billion by 2021, according to ResearchandMarkets. The company included dental restoration, orthodontics, periodontics, endodontics, infection control products, finishing and polishing products, and whitening products among other items in defining the market for evaluation.
The analyst firm attributes this growth to the rapid rise in the world’s geriatric population, growing dental tourism in emerging markets, rising rates of dental caries and other periodontal diseases, growing disposable incomes, greater demand for cosmetic dentistry, and increased dental care expenditures. But the company also expects high costs and limited reimbursements for dental care and a shortage of dental professionals will restrain some of the market’s growth.
The dental restoration segment accounted for the largest share of the global dental consumables market in 2015 due to its wide utilization by dental professionals in teeth regeneration and restoration procedures. Based on the type of end-users, ResearchandMarkets segmented the market into dental hospitals and clinics, dental academic and research institutes, and forensic laboratories.
In 2015, Europe commanded a major share of the dental consumables market due to its aging population, government expenditures, and high reimbursement rates. Also, implant dentistry got its start in Europe, so the penetration rate of dental implants there is very high. However, ResearchandMarkets expects the Asia-Pacific region to see the fastest growth through 2021 because of its growing geriatric population, increases in dental diseases, larger dental expenditures, and an increasing number of dental hospitals and clinics.
The bacterial and fungal pathogens that form biofilm on traditional dental implants pose a significant risk for infections, since biofilm resists antimicrobial drugs like antibiotics. Now, researchers at the University of Leuven in Belgium have developed a titanium-silica dental implant that reduces these infection risks by fending off pathogens before biofilm forms.
“Our implant has a built-in reservoir underneath the crown of the tooth,” said Kaat De Cremer, PhD, lead author of the study. “A cover screw makes it easy to fill this reservoir with antimicrobial drugs. The implant is made of a porous composite material, so that the drugs gradually diffuse from the reservoir to the outside of the implant, which is in direct contact with the bone cells. As a result, the bacteria can no longer form a biofilm.”
The researchers subjected the implant to various tests for use with chlorhexidine mouthwash. According to the results, Streptococcus mutans can’t form biofilms on the outside of the implant when the reservoir is filled with chlorhexidine. Biofilms that were grown beforehand on the implant were eliminated in the same way, meaning the implant is effective in both preventing and curing infections.
The study, “Controlled Release of Chlorohexidine from a Mesoporous Silica-Containing Macroporous Titanium Dental Implant Prevents Microbial Biofilm Formation,” was published by European Cells and Materials.
Aurelia, manufacturer of Amazing Gloves, introduces Aurelia Sonic Nitrile Gloves, its newest innovation in personal protection. Featuring Aurelia’s latest ultrathin construction to contour seamlessly to your hands, the gloves are thinner and more flexible than standard nitrile gloves and offered in striking indigo in sizes XS to XL. They also are powder-free, conforming with the US Food and Drug Administration’s Final Rule banning powdered gloves, which now is in effect. The gloves are packed in a 300-gloves-per-box standard dispenser.
For more information, call Aurelia at (877)-287-3542 or visit aureliagloves.com.
With PreVu Cosmetic Simulation Software, patients can visualize their treatment outcome—provided via chairside monitor or in the form of a take-home personalized visual aid—that positively supports their decision-making process toward accepting recommended treatment.
The software is designed to be simple, intuitive, and used by any member of the dental team. It also will work on any computer in the practice and even at home. With practice branding on the printouts of the simulations, dentists may see increased word-of-mouth referrals, according to the PreVu Dental.
In addition to the free demo package, PreVu Dental offers a whitening package, a perio package, and a premium package. All packages include 3 doctor licenses and a team license. Additional licenses can be purchased for a nominal fee.
For more information, call PreVu Dental toll-free at (855) 773-8848 or visit prevudental.com.
It’s a new year and time for a new format at The Wednesday Watch. Click now to see our newly designed broadcast, now featuring more stories in quicker sound bites. This week, hear how dentistry stacked up in the US News & World Report’s list of the Best Jobs for 2017. Find out how you can browse the history of the toothbrush from the privacy of your own home or office, and discover what some scientists are saying about regenerative endodontics.
|Did You Miss the Last DNN Broadcast? Watch it Now...|